Kidney Transplant News and Research RSS Feed - Kidney Transplant News and Research

A kidney transplant is an operation where a healthy kidney from one person (the donor) is transferred to a person who has little or no kidney function (the recipient).
Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation. [More]
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]

Transplant drugs may help defeat HIV

Drugs that are currently given to prevent organ rejection in patients who have received a transplant may offer a new approach to curing HIV, say researchers. [More]
Research findings suggest new strategy in fight against HIV infection

Research findings suggest new strategy in fight against HIV infection

New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of Transplantation, suggest a new strategy in the fight against HIV and AIDS. [More]
UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

UCLA Scientist Dr. Ira Kurtz has received a $3 million gift from the Donald T. Sterling Foundation to fund research on the structural properties of key proteins in the kidney that affect its function in health and disease. [More]
Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

A protein known to promote cancer appears to give the blood vessels strength and shape, researchers report. When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure of blood flow, said Dr. Jiliang Zhou, vascular biologist at the Medical College of Georgia at Georgia Regents University. [More]
Novel treatment strategy during transplantation surgery could spare patients from rejection

Novel treatment strategy during transplantation surgery could spare patients from rejection

Organ-transplant recipients often reject donated organs, but a new, two-pronged strategy developed by UC San Francisco researchers to specifically weaken immune responses that target transplanted tissue has shown promise in controlled experiments on mice. [More]
FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start. [More]
Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012. [More]
Minimally invasive robotic surgery: A safe alternative to traditional open surgery

Minimally invasive robotic surgery: A safe alternative to traditional open surgery

A collaboration of surgeons at Henry Ford Hospital and Medanta Hospital in India successfully transplanted kidneys into 50 recipients using an innovative robot-assisted procedure in which the organ is cooled with sterile ice during the operation. [More]
Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients. [More]
New discovery has potential to transform heart attack treatments

New discovery has potential to transform heart attack treatments

An Australian discovery has the potential to transform the treatment of a heart attack, after a new approach boosted heart function and reduced heart scarring in preclinical studies. [More]

CU researcher awarded NIH grant to study benefit of allopurino drug in lowering uric acid levels

Kidney disease poses one of the greatest burdens for people living with type 1 diabetes. A study newly awarded by the National Institutes of Health will look at whether lowering uric acid levels can prevent people with type 1 diabetes from needing hemodialysis or kidney transplant. [More]
Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic Delayed-release Tablets. [More]

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

Veloxis Pharmaceuticals A/S, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in kidney transplant recipients. [More]
Elementary school administrator donates healthy kidney to total stranger

Elementary school administrator donates healthy kidney to total stranger

Terie Cota, an elementary school administrator from Santa Maria, Calif., describes herself as an "average 56-year-old woman." She has been married 34 years, is the mother of four sons and grandmother of two little girls. But there is nothing average about Terie Cota because she chose to do something few others would think to do: She donated one of her healthy kidneys to a total stranger. [More]

Paired exchange and incompatible kidney transplant program launched by UAB

Ann Marie Reynolds, a 32-year-old who has been in and out of hospitals fighting chronic kidney disease since she was a teenager, had a less than 1 percent chance of receiving a kidney without the University of Alabama at Birmingham's groundbreaking organ donation system that helped her and two other hard-to-match patients get kidneys in a three-way, incompatible kidney exchange earlier this year. [More]

U.S. FDA grants Veloxis Orphan Drug status for Envarsus

Veloxis Pharmaceuticals A/S, today announced that Envarsus was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. [More]

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Baxter International Inc. today announced completion of CE marking in Europe for the VIVIA hemodialysis system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy. [More]

Paragonix Technologies files FDA Pre-Marketing Notification Application for Sherpa Pak Transporter

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration for its Sherpa Pak Transporter. The Sherpa Pak Transporter is indicated for the static hypothermic preservation of kidneys during transportation and eventual transplantation into a recipient, using cold storage solutions indicated for use with the kidney. [More]